



Radioligand therapy

REALISING THE POTENTIAL
OF TARGETED CANCER CARE



This report was produced by The Health Policy Partnership, with input from a steering committee who had full editorial control. It was supported by a grant from Advanced Accelerator Applications, a Novartis company, with additional support from Curium.

The
**Health Policy
Partnership**
[research, people, action]



January 2020

ACKNOWLEDGEMENTS

With many thanks to our steering committee members:

- Dr Josep Maria Borrás, Director, Catalonia Cancer Strategy, Spain
- Dr Jaroslaw Cwikla, Professor, Department of Radiology, University of Warmia and Mazury in Olsztyn, Poland
- Professor Ken Herrmann, Director, Clinic for Nuclear Medicine, University Hospital Essen, Germany
- Nikie Jervis, Specialist Nurse: Patient Support, Information & Education, NET Patient Foundation, UK

Additional thanks to:

- Dr Annibale Versari, Director, Oncology and Advanced Technologies, ASMN Reggio Emilia, Italy
- Dr Harald Lahner, Deputy Director, ENETS Center of Excellence, University Hospital Essen, Germany
- Dr Jamshed Bomanji, Head of Clinical Department, Institute of Nuclear Medicine, University College London Hospital, UK
- Dr John Buscombe, President, British Nuclear Medicine Society, UK
- Dr Valentina Ambrosini, Associate Professor of Nuclear Medicine, University of Bologna, Italy

About this report

This policy report has been drafted by The Health Policy Partnership, an independent research organisation, with input from a multi-stakeholder steering committee. Its aim is to create greater awareness of radioligand therapy as an innovative component of cancer care. The steering committee had full editorial control over content, which reflects consensus among the group. All members provided their time for free. The outputs of this project are intended for educational purposes only and do not relate to any particular product.

The report was supported by a grant from Advanced Accelerator Applications, a Novartis company, with additional support from Curium.

Contents

Glossary	6
Executive summary	7
Introduction	10
What is radioligand therapy?	12
How do radioligand therapy and nuclear medicine fit in with other treatments?	16
What are the barriers to integration of radioligand therapy into cancer care?	18
Conclusions and recommendations	23
Appendices	28
Appendix i. Radioligand therapy for neuroendocrine cancers	28
Appendix ii. Radioligand therapy for metastatic castration-resistant prostate cancer	30
Appendix iii. The potential of radioligand therapy in other disease types	32
References	34

Glossary

This glossary provides definitions of terms used throughout this report.¹⁻³

Biomarker is a naturally occurring molecule or other characteristic by which a particular disease or physiological process can be identified or monitored.

Chemotherapy slows or stops tumour growth with anti-cancer drugs.

Computed tomography (CT) scans use X-rays to create images of the body at different angles. A computer uses these images to develop a 3D image. X-rays are good at imaging bones and tissue changes caused by cancer or other disease.

Gene therapy utilises genes and genetic modification to treat cancer.

Hormone therapy is effective for cancers that use hormones for growth. Therapies either block the body's ability to produce hormones or change how hormones function.

Immunotherapy utilises the immune system in a variety of ways. Approaches include directly attacking the cancer (such as monoclonal antibodies) or supporting the immune system to work against the cancer (such as vaccines, cytokines or interferons).

Ligand is a molecule that selectively binds to a different molecule. Examples are antigens binding to an antibody, or a hormone binding to a receptor on a cell.

Magnetic resonance imaging (MRI) uses magnetic fields and radiofrequency waves to take images of different parts of the body. It is good at imaging soft tissues, particularly the brain.

Metastatic cancer occurs when a cancer has spread to different parts of the body from where it originated.

Neuroendocrine cancers are a group of cancers, sometimes referred to as neuroendocrine neoplasms (NENs) – which includes neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs) – that occur in neuroendocrine cells.

Positron-emission tomography (PET) scans use radioactive tracers to produce 3D images of the inside of the body. The scan shows how organs and tissues function, and also can provide evidence of the presence or absence of cancer.

Radioiodine or radioiodine 131 is a radioactive form of iodine that is used to treat thyroid cancer.

Radioisotope is an unstable form of a chemical element that emits radiation as it breaks down to a stable form. Radioisotopes may occur naturally or be made in a laboratory.

Radioligand is a cancer-targeting molecule, or ligand, attached to a radioisotope. By choosing different radioisotopes to attach to the same type of ligand, the process can be tailored to either diagnose or treat certain types of cancer.

Radiotherapy uses internal or external radiation to kill or reduce the size of a tumour. Radiotherapy only affects the tumour and surrounding tissue.

Radiotracer is a radioisotope that emits gamma rays and is used for diagnostic purposes.

Single-photon emission computed tomography (SPECT) combines a CT scan with a radiotracer, showing how blood and other fluids move through the body to organs and tissues. It can be used to investigate metabolism and organ function.

Targeted therapy is a category of cancer treatment that exploits differences between normal and cancerous cells, and includes targeting and killing cancer cells (such as radioligand therapy) and stopping cancer growth (such as tyrosine kinase inhibitors).

Theranostics treats cancer using highly targeted and personalised therapy based on specific diagnostic tests.

Tumour antigen is a substance such as proteins, glycoproteins, glycolipids, or carbohydrates expressed on the surface of tumour cells that elicits an immune response. They may be restricted to tumour cells only, or present on both tumour cells and normal cells.

Tumour board is a meeting of the cancer care team that plans and assesses treatment. It may include medical and radiation oncologists, surgeons, pathologists, nurses and other healthcare professionals. It may also be called a multidisciplinary tumour board.

Executive summary

Despite progress in many areas of cancer care, important gaps remain.


Many people do not have effective treatment options, particularly for aggressive or rare forms of cancer,⁴ and new strategies are needed to improve not just survival, but quality of life.⁵ One such emerging treatment modality is called radioligand therapy.

Radioligand therapy delivers radiation directly to select types of cells, and it is gradually emerging as an important component of cancer care. It has been shown to improve overall survival and quality of life for many people with neuroendocrine cancers and castration-resistant prostate cancer that has metastasised to the bone.⁵⁻⁹ However, it has only recently been introduced into cancer care guidelines for these types of tumours.¹⁰⁻¹⁹

How does radioligand therapy work?

A cancer cell has specific molecules on its surface which may not be present on healthy cells. Radioligand therapy utilises this structural difference to deliver radiation directly to cancer cells, regardless of where they are in the body.²⁰⁻²² Radioligands are made of two parts: a ligand, which finds cancer cells that have a particular surface molecule; and a radioisotope, which provides radiation.²⁰ By choosing different radioisotopes to attach to the same type of ligand, the process can be used to either diagnose or treat certain types of cancer.²⁰⁻²³ As the radiation works over very short distances and can be directed specifically to cancer cells, the treatment is generally well tolerated with self-limiting side effects.^{20 21 24 25}

Radioligand therapy may contribute to ongoing efforts to provide personalised and targeted treatments to cancer patients. It can be targeted to the unique characteristics of the cancer being treated, which may help improve the efficacy of treatment.²³



What are potential barriers to integration of radioligand therapy into cancer care?

Radioligand therapy is a relatively new treatment approach and its integration into clinical practice will require strengthening and alignment of a number of factors. Many oncologists, radiation oncologists and even some nuclear medicine specialists, who are typically those who prescribe radioligand therapy, may not be fully aware of the many applications of radioligands,²⁶⁻²⁸ while patients may have preconceived negative perceptions around the use of radioactive substances.^{22 26 29 30}

There are very few healthcare professionals trained in radioligand therapy,^{22 27} which restricts use of the approach to a small number of specialist centres^{27 28} and may limit their ability to participate in all relevant multidisciplinary care teams and tumour boards.^{27 28 31 32}

The regulatory frameworks for radioligands must also evolve to suit this emerging treatment modality. This may affect who provides treatment, and how.^{29 33 34} Other policy advances are needed in terms of supply of radioisotopes and nuclear waste; some radioisotopes do not require significant specialist waste collection or storage, while others do,³⁵ so a 'one size fits all' nuclear waste disposal policy is not appropriate.

Finally, the limited availability of representative clinical and economic data on radioligand therapy poses challenges.^{26 30 32 36-38} These barriers contribute to variations in availability of radioligand therapy across Europe and must be overcome if this treatment modality is to become available to all people who may benefit from it.



What can decision-makers do to ensure integration of radioligand therapy into cancer care?

There are many actions that can be taken to build radioligand therapy into cancer care plans and encourage its appropriate utilisation in practice. These will require concerted action by decision-makers, nuclear medicine and the broader cancer clinical community, hospital managers, patient organisations, researchers and industry. Actions include:

- **Increase** awareness of radioligand therapy and the role of nuclear medicine among decision-makers, people with cancer and the clinical cancer community.
- **Harmonise** education and training standards across Europe for nuclear medicine specialists and all members of the multidisciplinary cancer team.
- **Ensure** that nuclear medicine specialists have adequate capacity to participate in multidisciplinary cancer care processes.
- **Develop** clear processes and patient pathways for care in each national context.
- **Ensure** adequate hospital capacity and resources for delivery of radioligand therapy to meet current and future demand.
- **Incorporate** radioligand therapy into national, regional and local cancer plans.
- **Establish** clear, consistent regulatory frameworks for the use of radioisotopes spanning approval, funding and reimbursement.
- **Ensure** continued supply and appropriate disposal policies.
- **Invest** in real-world data on radioligand therapy to better understand patient outcomes and cost-effectiveness.
- **Identify and share** best practices to optimise and standardise care.



Introduction

Despite progress in many areas of cancer care, too many people still do not have effective treatment options, particularly those with aggressive or rare forms of cancer.⁴ New strategies are needed to improve not just survival, but quality of life.⁵ Cancer is the second leading cause of death globally.³⁹ In Europe there were almost 4.3 million new cases in 2018, and incidence and mortality rates are set to rise significantly in the future.⁴⁰

Our growing understanding of the biology of cancer has led to new opportunities for increasingly precise, targeted and effective treatment.²⁰ Greater knowledge of the differences between tumour cells and normal cells has allowed the development of treatments that can target tumour cells directly, minimising damage to healthy cells⁹ with greater efficacy and less toxicity for patients.

One such example is radioligand therapy, which delivers radiation directly to specific cells. Targeted radiation has existed for decades. For example, radioiodine was first used to treat overactive thyroid glands and subsequently thyroid cancer in the 1940s.⁴¹⁻⁴⁴ Because the thyroid absorbs significantly more iodine than any other organ, radioiodine is taken directly to the thyroid and delivers radiation to kill cancerous cells. Radioiodine remains a mainstay of treatment for thyroid cancer today. This principle of targeted radiation has evolved from organ-level precision to cellular-level precision in line with scientific advances; radioligands bind to certain types of cancer cells wherever they are located in the body and can therefore be used for targeted diagnosis and treatment.

Radioligand therapy is currently used in a small number of cancers, but the approach looks promising in other cancer and non-cancer conditions as well. It is frequently used for metastatic neuroendocrine cancers and bone metastases in castration-resistant prostate cancer (mCRPC),^{20 33 45} and has been shown to improve overall survival and quality of life for many patients.⁵⁻⁹ People with these types of cancers typically have limited therapeutic options, and radioligand therapy presents a new opportunity for treatment. Researchers are also exploring how the approach could be utilised in other conditions, but further data are needed to understand its full potential.

The integration of radioligand therapy into clinical practice requires new models of care, potentially more than other new treatment modalities. Because it uses radioactivity delivered into the bloodstream that can reach cells across the whole body, radioligand therapy raises specific issues for patient education, as well as hospital capacity, infrastructure and nuclear waste disposal. Integrating radioligand therapy into clinical practice requires revision of the traditional multidisciplinary team to ensure inclusion of relevant specialists for both diagnostic and therapeutic discussions. These potential barriers must be understood and overcome if this treatment modality is to become available to all people with cancer who may benefit.

This report aims to provide decision-makers around Europe with a grounding in radioligand therapy, offering evidence-based recommendations on how to create an enabling environment for its wider integration into cancer care. Based on a literature review and expert consultation, this report will first explain what radioligand therapy is and how it is used, and then explore some of the challenges and opportunities for decision-makers and other stakeholders to ensure this treatment modality is made available to all patients who need it.

What is radioligand therapy?

Radioligand therapy is an innovative approach to cancer treatment that delivers radiation directly to select types of cells.



Cancer cells have particular molecules on their surface which may not be present on healthy cells or are over-expressed in cancerous cells. Radioligand therapy utilises this structural difference to deliver treatment. Radioligands are made of two parts: a ligand, which is able to find cancer cells with a particular tumour target, and a radioisotope for treatment (Figure 1).²⁰ The ligand finds cells that present the tumour target and delivers radiation directly to these cancerous cells, regardless of where they are in the body.²⁰⁻²² At present, radioligand

therapy is typically given to people with metastatic, often progressive cancer who have undergone other types of cancer treatment without success.⁹

Radioligands can be used for both imaging and treatment.




Different radioisotopes have different properties; some can be used for imaging, others for therapy and some have applications for both.⁴⁶ By choosing different radioisotopes to be attached to the same type of ligand, the process can be tailored to either diagnosing or treating certain types of cancer.²⁰⁻²³ Combining these processes is known as theranostics.^{9,47} Box 1 and Box 2 outline key aspects of imaging and treatment with radioligands; Box 3 describes different types of radiation and their properties.

FIGURE 1. Radioligand therapy is an evolution of technology from imaging to therapy



Radioligand therapy may contribute to ongoing efforts to provide increasingly personalised and targeted treatments to cancer patients.



It can be adapted to the unique characteristics of the cancer being treated, for example by choosing different therapeutic radioisotopes, or altering dosing or the number of treatment cycles.^{6,22,23,48,49} This can help improve the efficacy of treatment.²³



BOX 1. Radioisotopes

can often improve the accuracy of diagnosis

During diagnosis, a person undergoes scans to differentiate between cancerous and non-cancerous tissue. Scans may include positron-emission tomography (PET), computed tomography (CT), single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI).⁵⁰

PET scans use radioisotopes, or radiotracers, that emit gamma radiation to show how the cells in the body function. They can detect processes such as metabolism and blood flow to diagnose different health conditions.⁵¹ To diagnose certain cancers, a ligand is attached to the radioisotope to find cancer cells wherever they are in the body.⁵¹ The resulting images provide a complex view of the cancer, allowing healthcare professionals to diagnose and stage the cancer and see the extent of metastases.^{21,51,52}

Improving our understanding of tumour metabolism and cancer biology through imaging may help treat cancers in an increasingly personalised way. In some situations, PET scans can be more sensitive than conventional imaging with CT, SPECT and MRI, and the additional functional information PET provides may help with planning subsequent treatment with greater confidence.^{9,53-57} The images may even be used as a biomarker to predict who might benefit from treatment or to monitor treatment response.⁵⁸

**BOX 2. Radioligand therapy**

is an emerging treatment modality for metastatic and resistant cancers

Once the cancer has been detected and characterised with a PET scan, a therapeutic radioisotope is attached to the same type of ligand and used to kill the cancer cell by damaging its DNA.²² As the highly targeted alpha or beta radiation works over short distances, the treatment is generally well tolerated with self-limiting side effects.^{20 21 24 25}

The systemic and targeted nature of radioligand therapy provides an opportunity to treat metastatic cancers,⁵⁹ which are responsible for up to 90% of cancer-related mortality.⁶⁰ They tend to be difficult to treat because tumours are found in multiple locations around the body, so treatment options such as surgery and external beam radiotherapy are less effective.⁵⁹

Radioligand therapy may also be an effective treatment option for cancers that are resistant or unresponsive to other treatment approaches, such as chemotherapy.⁶¹

**BOX 3. Different radioisotopes**

emit radiation with various useful properties

As radioisotopes decay, they give off radiation with different levels of energy that are effective over different distances. It is this energy that is harnessed to either diagnose a cancer or kill cancer cells. There are three types of radiation.^{46 62}

- ☛ **Alpha** has very high energy and a short range – approximately the width of 1–3 cells.
- ☛ **Beta** has a lower energy and longer range.
- ☛ **Gamma** has the lowest energy and longest range.

Diagnostics typically use gamma radiation because its longer range allows detection by scanners.⁶³ Treatment generally utilises alpha and beta radiation because the high energy is emitted over a short range, meaning surrounding cells receive less radiation.²⁰

Regardless of radiation type, every radioisotope has a characteristic half-life, which denotes how long the atoms will remain radioactive.⁶⁴

- ☛ **A longer half-life** means the radioisotope can be produced in a specialised, central location and subsequently delivered to hospitals and clinics. However, this means that the radioactivity will be detectable for longer.
- ☛ **A shorter half-life** means the radioisotopes must be prepared closer to the time and site of treatment.

There are various terms used for radioligand therapy, including peptide-receptor radionuclide therapy (PRRT), systemic radiation therapy, targeted radionuclide therapy, targeted radiotherapy and molecular radiotherapy. Sometimes the ligand is an immune cell, in which case the approach is known as radioimmunotherapy. This report uses the term radioligand therapy.

How do radioligand therapy and nuclear medicine fit in with other treatments?

The history of radioligand therapy provides a strong foundation for the modern cohort of therapies that are beginning to enter into clinical practice. As mentioned previously, the use of radioiodine to treat people with thyroid cancer is well established;⁴²⁻⁴⁴ this approach has inspired wider applications of radioligands for imaging and therapy.

Radioligands are gradually emerging as an important component of cancer care. However, their use as a therapy has recently been introduced into cancer care guidelines for NETs¹⁰⁻¹⁴ and mCRPC¹⁵⁻¹⁹ (Figure 2). The approach is also currently being explored both as a standalone treatment approach and in combination with other treatment modalities:


- Combining different radioisotopes with the same type of ligand could be extremely beneficial. Radioisotopes with varying ranges could potentially treat both small and large tumours at the same time and may improve survival.⁶⁵⁻⁶⁶
- Using radioligand therapy in conjunction with other therapies, for example radiotherapy, chemotherapy or certain targeted therapies, may be a promising way to enhance efficacy of both treatments,⁷⁻²² especially for aggressive cancers.

Appropriate integration of radioligand therapy into clinical cancer care will require close collaboration and clear workflows across numerous specialists and disciplines involved in cancer care.²²⁻²⁹⁻³⁴⁻³⁵ A multidisciplinary team includes healthcare professionals specialising in different disciplines. In cancer care this can include oncologists, radiation oncologists, surgeons, nuclear medicine physicians and other oncology and non-oncology specialties such as urology or endocrinology. Despite the fact that radioligand therapy is typically administered by nuclear medicine specialists, the specialism does not always play an active role in multidisciplinary cancer care teams or therapeutic tumour boards. Through its applications to both diagnostics and therapy, nuclear medicine will have a growing role in cancer care,⁶⁷ and the greater integration of radioligand therapy into clinical cancer care requires far more emphasis on multidisciplinary working. Such an approach is particularly important as radioligand therapy is unlikely to become the sole therapeutic approach for people with cancer.³⁰

The newest applications of radioligands focus on NETs and bone metastases in mCRPC, with research ongoing in many other conditions. *Appendices i-iii* highlight how the approach is used in these different diseases.

To integrate radioligand approaches in cancer care, there are many potential challenges that need to be addressed. The next sections outline some of these barriers and potential solutions.

FIGURE 2. Timeline of major advances in radioligand therapy and cancer care⁴¹⁻⁴²⁻⁶⁸⁻⁸¹



What are the barriers to integration of radioligand therapy into cancer care?



Radioligand therapy as a modality has developed rapidly in recent years but its integration into clinical practice will require a number of factors to align, including: greater understanding and awareness among patients and healthcare professionals; coordination and collaboration

between medical oncologists, nuclear medicine physicians and other specialties involved in delivering cancer care; hospital capacity planning – both physical and human resources – to deliver radioligand therapy safely and effectively; and effective nuclear waste disposal protocols tailored to the different types of therapy.^{34 35 82}

Understanding of radioligand therapy

Limited understanding of radioligand therapy among healthcare professionals may lead to fewer referrals of eligible patients.

Many oncologists, radiation oncologists, and even some nuclear medicine specialists may not be fully aware of the many applications of radioligands.²⁶⁻²⁸ Referring clinicians may also be concerned about potential side effects of radioligand therapy, may prefer other approaches with which they are more familiar, or may fear losing their patients to the care of other specialists and hospitals.^{22 26 32 36}

Patients, too, may not fully understand what radioligand therapy is and have preconceived negative perceptions around its use of radioactive substances.^{22 26 29 30} Despite nuclear medicine approaches being generally safe and well tolerated, negative perceptions may make people wary of their use. Furthermore, people may confuse radioligand therapy with radiotherapy, not fully understanding what the approach involves.³⁰ More time and educational materials are needed to properly explain to patients what radioligand therapy is and describe its relative risks and benefits.^{30 36}

Professional capacity, training and workforce planning

Professional training is an important area for development.

There are very few healthcare personnel appropriately trained in radioligand therapy,^{22 27} which restricts use of this approach to a small number of specialist centres.^{27 28} Educating the multidisciplinary team on radioligand therapy is also important; however, there seem to be few consistent educational initiatives appropriate to the whole cancer care team. Furthermore, as radioligand therapy and the discipline of nuclear medicine continue to evolve, education must be updated.³⁰ The existing cohort of trained and experienced personnel needs to grow, especially if new types of radioligand therapy are approved and their clinical use increases. Limited numbers of specialists, and healthcare professionals more broadly, could become a significant barrier to care in the future.

Limited capacity and resources may restrict multidisciplinary working and integration of radioligand therapy into clinical practice. The lack of consistent processes and resources for multidisciplinary working in hospital settings can limit implementation of multidisciplinary teams in cancer care.^{31 38} There can be confusion as to the roles and responsibilities of different members of the multidisciplinary team^{29 83} or how to include nuclear medicine specialists in tumour boards in non-specialist hospitals. In addition, new processes around radioligand therapy may be disruptive to current cancer care pathways, which may be a barrier in itself.²² In some hospitals, the limited number of nuclear medicine specialists may simply mean there is not enough capacity for them to participate in every multidisciplinary tumour board.^{27 28 31 32} These workforce issues may compound the gaps in training described above.³⁶

Models of care

Providing radioligand therapy requires intensive planning with clear workflows and processes.^{22 27 34 35} However, a lack of harmonised, up-to-date guidelines and standardised treatment protocols is a challenge to providing consistent care in line with the latest scientific advances.^{84 85} Furthermore, different countries and even different hospitals often have disparate ways of organising the delivery of radioligand therapy and composition of multidisciplinary teams.^{26 36 38 49} For example, the nuclear medicine physician is a core member of the multidisciplinary team in accredited centres for neuroendocrine tumours,³² but protocols and patient pathways for delivering treatment vary considerably between different centres.³⁶

Physical capacity and resourcing

Healthcare systems may not be adequately prepared for greater utilisation and integration of radioligand therapy. There are significant geographical variations in access to care, as centres that provide radioligand therapy tend to be concentrated in a small number of metropolitan areas or in certain regions.^{27 28 38} As a result, people often travel significant distances, and even across countries, for treatment.²² The approach is frequently provided as an inpatient procedure, which may require isolation of patients in lead-lined rooms. As the number of people eligible for radioligand therapy grows and demand increases, existing treatment centres may not have sufficient capacity to provide inpatient care. For example, there may be additional requirements for equipment or storage facilities for contaminated materials.^{26 36} Such resource challenges may cause delays in making the approach accessible to patients.

Ensuring a consistent supply of radioisotopes can also be challenging. Most medical radioisotopes are created in a small number of nuclear reactors, which are becoming increasingly unreliable due to old age.⁸⁶⁻⁸⁸ Reactors frequently shut for planned or unplanned maintenance, and there can be additional logistical difficulties in post-production processing and distribution to hospitals.⁸⁶⁻⁸⁹ Such unpredictability in the global supply chain has directly impacted availability of diagnostic tests and medical procedures involving certain radioisotopes.^{86 88} International, European and national decision-makers have been working to improve the reliability of medical radioisotope supply, but as demand for all types of radioisotopes continues to grow, sustained efforts are needed to secure their supply and delivery.⁸⁷⁻⁹¹

Evolving legislation and policy

Given the recent introduction of radioligand therapy into cancer care, the regulatory and reimbursement frameworks used for it are not always clear or appropriate, and may need adapting. Radioligand therapy approaches are initially used in the context of research and clinical trials, and therefore under national legislation on use of experimental therapies.⁴⁹ Wider clinical use requires approval by the European Medicines Agency, and subsequent approval and reimbursement in each member state. However, both international and national regulatory frameworks developed for conventional medicines may need to be adapted to be appropriate for the evaluation of radioligand therapy and radioisotopes.⁹² This is not unique to radioligand therapy, as the value frameworks embedded into health technology assessment and reimbursement processes may also require modification to be suitable for other non-medicinal approaches such as radiotherapy and surgery.⁹³

Regulatory frameworks do not fully account for differences between radioisotopes. For example, regulatory evaluation processes may be particularly unsuitable for radioisotopes with a short half-life. Such rigid frameworks can therefore restrict the use of certain types of radioligand therapy or affect who provides treatment, and how.^{29 33 34}

The categorisation and regulatory frameworks for approval of theranostics also need to evolve. Theranostics presents a crossover between diagnosis and treatment.⁹⁴ In some countries, the evaluation and approval process for radioligand imaging is different to that for radioligand therapy,^{30 38} impeding use of theranostics and leading to variations in availability to patients.

Waste disposal policies also require careful planning, as different radioisotopes require different processes.³⁵ Although some radioisotopes do not require significant specialised waste collection or storage, these processes may be required in other cases – and a ‘one size fits all’ nuclear waste disposal policy is therefore not appropriate. As demand increases, there may be additional pressures on such processes.^{26 36}

Data and research

The limited availability of representative clinical data on radioligand therapy also poses a challenge.^{26 32 36-38 49} For example, analysis of existing clinical trial data may be hindered by the heterogeneity of patient groups with advanced cancer⁹ and the retrospective nature of the data.⁴⁹ In the field of neuroendocrine tumours, the low number of people affected presents an additional barrier.³⁷ A further challenge is the absence of a clear or consistent understanding of what constitutes a response to radioligand therapy.^{9 20 49 95} The absence of economic data on radioligand therapy may also pose a barrier for funding and reimbursement within healthcare systems;^{26 30 36 38} hospitals may want data on budget impact before agreeing to fund radioligand therapy.²⁶

These data challenges contribute to significant variability in availability of radioligand therapy across Europe.^{20 22} As the use of radioligand therapy increases in cancer care there will be more real-world data reflecting longer-term experiences of patients.³⁶ This information will be important to support greater understanding of radioligand therapy's impact on patient outcomes and resource use, and guide future use.

Conclusions and recommendations

Radioligands are an innovation driven by our increasing understanding of the molecular biology of cancer and the role of radiation in cancer care. The use of radioligands for diagnostics is well established, with PET scanners being a mainstay in imaging departments across Europe. For people undergoing radioligand therapy, there are proven improvements in survival and quality of life.

Radioligand therapy is gradually becoming an important component of care for certain types of cancer. To ensure it can be appropriately embedded into cancer care and made available to patients – now and in the future – cancer plans and multidisciplinary teams must integrate and increase the visibility of nuclear medicine within cancer care, and work to ensure that radioligand therapy is included in appropriate cancer care processes.^{30 34 35 82} A shift towards integrated multidisciplinary working and re-evaluation of discrete, independent health specialties is essential – not just for radioligand therapy but for all cancer treatment.

Efforts to strengthen integration and expand the use of radioligand therapy will require concerted action. The inclusion of radioligand therapy in future cancer plans and cancer-related policies will be essential, as well as proactively addressing hospital capacity issues to enable the provision of safe, high-quality care. While this therapy may be best delivered by centres of excellence, health system planning must ensure that such centres are reasonably distributed in order to minimise geographical inequities in care. European-level efforts may also help mitigate some of the existing challenges for radioligand therapy, particularly in terms of setting frameworks and guidelines for multidisciplinary working, care pathways and training standards. The EU also has an important role to play in fostering exchange of best practice and investing in research to address existing data gaps, securing supply of radioisotopes and clarifying regulatory issues.

Policy recommendations

We call on decision-makers at the European and national levels to integrate radioligand therapy as a potential treatment option into all cancer plans and relevant health policy frameworks.


There are 10 key actions that can be taken to overcome barriers to greater integration of radioligand therapy in clinical cancer care. These will require concerted action by multiple stakeholders including decision-makers, nuclear medicine and the broader cancer clinical community, hospital managers, patient organisations, researchers and industry.



Low awareness and understanding

ACTION NEEDED


- Increase awareness of radioligand therapy and the role of nuclear medicine among decision-makers, people with cancer and the clinical cancer community



Limited professional capacity, training and workforce planning

ACTION NEEDED


- Harmonise education and training standards across Europe for nuclear medicine specialists and all members of the multidisciplinary cancer team
- Ensure that nuclear medicine specialists have adequate capacity to participate in multidisciplinary cancer care processes



Unclear models of care

ACTION NEEDED

- Develop clear processes and patient pathways for care in each national context



Inadequate physical capacity and resourcing in hospitals

ACTION NEEDED


- Ensure adequate hospital capacity and resources for delivery of radioligand therapy to meet current and future demand



Evolving legislation, regulation and policy

ACTION NEEDED

- Incorporate radioligand therapy into national, regional and local cancer plans
- Establish clear, consistent regulatory frameworks for the use of radioisotopes spanning approval, funding and reimbursement
- Ensure continued supply and appropriate disposal policies




Lack of data and research

ACTION NEEDED

- Invest in real-world data on radioligand therapy to better understand patient outcomes and cost-effectiveness
- Identify and share best practices to optimise and standardise care

The mechanism of radioligand therapy suggests it may have wide applications and could become an important pillar of treatment for many types of cancers and other diseases. Further research and enhanced real-world data collection will help efforts to identify opportunities to use this highly personalised branch of medicine, as well as optimising current delivery.

Cancer is the second most frequent cause of mortality and morbidity in Europe, and it is expected that the burden of disease will continue to grow in the coming years. As our understanding of this complex and diverse group of diseases grows, it becomes increasingly clear that we must have a broad range of tools that are adaptable and can be personalised. Current cancer care often fails to meet the needs of people with rare, resistant or metastasised forms of cancer. Radioligand therapy may help to address this gap and provide life-enhancing treatment for people with limited therapeutic options, playing an important role in realising the potential of personalised, targeted healthcare. It is up to decision-makers to act now to ensure that every person with cancer receives appropriate and adaptable care as soon as they need it.



Appendix i. Radioligand therapy for neuroendocrine cancers


Neuroendocrine cancers are a diverse group of cancers affecting cells that produce and release hormones, frequently occurring in the gastrointestinal tract, pancreas and lungs, among other locations.^{7 20 25 62 96} Neuroendocrine cancers, also known as neuroendocrine neoplasms (NENs), include both neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs). These cancers differ depending on their site of origin. The majority of people are diagnosed with advanced metastatic cancer, for which the five-year survival rate is less than 50%.⁷ However, some neuroendocrine cancers may be extremely slow to develop.^{25 97 98} As these are rare cancers,^{25 96} collecting epidemiological or clinical data across small populations can be extremely challenging.^{22 25} However, the incidence is growing rapidly and they are gradually becoming less rare.⁹⁹⁻¹⁰¹

The variability and rarity of neuroendocrine cancers present challenges in diagnosis and management. Many people remain asymptomatic for a long time and symptoms can be nonspecific, impeding referral and diagnostic pathways.¹⁰²⁻¹⁰⁴ Furthermore, the rarity of these cancers means that healthcare professionals may have limited experience in recognising them.^{31 32 36 37} As a result, the average time to diagnosis from symptom onset is more than four years,^{102 104} and incorrect diagnoses are common.

It is difficult to run clinical trials in neuroendocrine cancers due to their rarity.³¹ The impact of this may be mitigated through international collaborative research efforts such as those led by the European Neuroendocrine Tumor Society (ENETS) and European Reference Networks, which also offer opportunities for collection of real-world data across multiple countries.

Therapeutic options can be limited for many people with neuroendocrine cancers. The diversity of these cancers necessitates a variety of therapeutic approaches,^{22 25} including surgery, targeted therapy, chemotherapy, interventional radiotherapy, hormone therapy, immunotherapy and radioligand therapy.^{10 11 96 105-108} Not every person will be eligible for all treatment approaches; where possible, combinations of approaches are commonly used to optimise outcomes. For people with metastatic neuroendocrine cancers, surgery may not be a curative option, leaving them with extremely limited therapeutic options.^{5 25}

Radioligands are becoming well established in the diagnosis and management of neuroendocrine cancers. The past 15 years have seen increasing uptake of radioligand therapy and official integration into care pathways and guidelines.²⁵ A PET/CT using radiotracers is now seen as the 'gold standard' in imaging for neuroendocrine cancers,¹⁰³ and is increasingly common across Europe.¹⁰⁹



To expand and optimise the use of radioligands for neuroendocrine cancers, more research is needed. A number of guidelines for radioligand therapy exist but, as experience and evidence grow, these will need to be updated and consensus-driven standardised therapeutic protocols developed.^{7 22 49 62} More evidence is needed to verify the impact of radioligand therapy through prospective randomised controlled trials.⁸⁵ Specific areas requiring further research and data include response predictors, effectiveness in different sites of disease or rates of growth, opportunities to utilise alpha-emitting radiation, and the combination of radioligand therapy with other approaches.^{6 36 62 96}

Appendix ii. Radioligand therapy for metastatic castration-resistant prostate cancer

Prostate cancer is the most commonly diagnosed cancer among men in Europe.¹¹⁸ More than 1.5 million men live with the condition.¹¹⁹ Recent years have seen a rapid increase in detection rates due to screening initiatives and awareness-raising efforts.¹¹⁸ Despite this, prostate cancer remains the third most frequent cause of cancer mortality in men.¹¹⁸

mCRPC is a type of prostate cancer that does not need hormones to grow and so does not respond to hormone therapies. It frequently metastasises to bone, organs and soft tissue.^{8,29} Bone metastases are particularly difficult to treat and can reduce mobility, quality of life and overall survival, and increase treatment costs.^{8,29,120} It is estimated that in the UK there are 40,000 new cases of mCRPC each year, and the incidence of this type of cancer is increasing.¹²¹

Treatments for mCRPC are increasingly varied, requiring expert input. Options include chemotherapy, immunotherapy, external beam radiotherapy and radioligand therapy.^{8,29} Clinical presentation of mCRPC can be so diverse that, despite the existence of clinical guidelines, it is not always clear which treatment options are most appropriate for each individual.²⁹

Most people with prostate cancer receive radioligand therapy only after other treatments have been unsuccessful. Radioligand therapy is usually given to people with mCRPC and bone metastases under palliative conditions once other treatments, such as chemotherapy and other approaches, have failed.⁹ However, more research is needed to understand the potential benefit of using radioligand therapy earlier in the treatment course for people with mCRPC and bone metastases.²⁹ To achieve this, we need further prospective data to better understand the impact and role of radioligand therapy in mCRPC,^{9,33,48} as well as randomised head-to-head trials against other treatment options.⁴⁸

radioligand therapy improves quality of life^{8,9}

imaging with radioligands has high sensitivity and specificity¹²²

Radioligands are emerging tools in the diagnosis and treatment of mCRPC. Radioligand imaging and therapy for bone metastases have been part of clinical practice for more than five years.³⁴ Over this time, it has been shown that:

radioligand therapy improves survival and is well tolerated^{8,9,33,34,48}


However, not everyone with mCRPC will respond to radioligand therapy: it is estimated that 10–25% of people treated will still experience disease progression.¹²³

As experience grows of using radioligand therapy in prostate cancer, new care models and protocols will need to be developed. Urologists' and oncologists' awareness or experience of nuclear medicine approaches may be limited, hindering referrals or multidisciplinary working. Therefore, as radioligand therapy becomes more common in mCRPC, additional awareness-raising and multidisciplinary care models may be needed.^{22,34}


Appendix iii. The potential of radioligand therapy in other disease types

Extensive research is underway to investigate the possible application of radioligands in a number of cancer and non-cancer conditions. *Table 1* outlines just some of the conditions under investigation.

TABLE 1. Conditions currently under investigation for use of radioligand imaging or therapy



CONDITION	DESCRIPTION
Lymphoma and non-Hodgkin's lymphoma ^{22 124}	A cancer that begins in lymphocytes, an immune system cell found in lymph nodes, bone marrow and other locations ¹²⁵
Breast cancer ^{126 127}	A cancer of the cells in the breast, typically in milk-producing glands or ducts ¹²⁶
Melanoma ³³	A type of skin cancer in cells called melanocytes ¹²⁹
Multiple myeloma ¹³⁰	A cancer that develops in bone marrow plasma cells ¹³¹
Lung cancer and neuroendocrine cancers in the lungs ¹²⁶	A cancer in the lungs or airways ¹³²
Pancreatic cancer ¹³³	A cancer in the pancreas (a gland in the digestive system) ¹³⁴
Atherosclerosis ²³	A build-up of fat and other material inside arteries, which typically manifest as ischaemic heart disease, ischaemic stroke and peripheral artery disease ¹³⁵



References

- Merriam-Webster. 2019. Medical Dictionary. Available from: <https://www.merriam-webster.com/medical> [Accessed 30/09/19]
- National Institute of Health: National Cancer Institute. 2019. NCI Dictionary of Cancer Terms. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms> [Accessed 30/09/19]
- Cancer.Net. 2019. Cancer Terms. Available from: <https://www.cancer.net/navigating-cancer-care/cancer-basics/cancer-terms> [Accessed 30/09/2019]
- Rahbar K, Bode A, Weckesser M, et al. 2016. Radioligand Therapy With ¹⁷⁷Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. *Clin Nucl Med* 41(7): 522-8
- Khan S, Krenning EP, van Essen M, et al. 2011. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [¹⁷⁷Lu-DOTA0,Tyr3]octreotate. *J Nucl Med* 52(9): 1361-8
- Baum RP, Kulkarni HR, Singh A, et al. 2018. Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms. *Oncotarget* 9(24): 16932-50
- Hirmas N, Jadaan R, Al-Ibraheem A. 2018. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. *Nucl Med Mol Imaging* 52(3): 190-99
- Nilsson S. 2016. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. *Curr Oncol Rep* 18(2): 14
- Virgolini I, Decristoforo C, Haug A, et al. 2018. Current status of theranostics in prostate cancer. *Eur J Nucl Med Mol Imaging* 45(3): 471-95
- Falconi M, Eriksson B, Kaltsas G, et al. 2016. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. *Neuroendocrinology* 103(2): 153-71
- Pavel M, O'Toole D, Costa F, et al. 2016. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. *Neuroendocrinology* 103(2): 172-85
- National Comprehensive Cancer Network. 2019. *NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors*. Washington, DC: NCCN
- European Association of Urology. 2019. Prostate Cancer Oncology Guideline. Available from: <https://uroweb.org/guideline/prostate-cancer/> [Accessed 08/10/19]
- National Institute for Health and Care Excellence. 2018. Lutetium (¹⁷⁷Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours. [Updated 28/08/18]. Available from: <https://www.nice.org.uk/guidance/TA539/chapter/1-Recommendations> [Accessed 6/12/19]
- Parker C, Gillessen S, Heidenreich A, et al. 2015. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 26(suppl_5): v69-v77
- Poeppel TD, Handkiewicz-Junak D, Andreeff M, et al. 2018. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging* 45(5): 824-45
- Basch E, Loblaw DA, Oliver TK, et al. 2014. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. *J Clin Oncol* 32(30): 3436-48
- National Comprehensive Cancer Network. 2019. *NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer*. Washington, DC: NCCN
- National Institute for Health and Care Excellence. 2019. Prostate Cancer: diagnosis and management. [Updated 01/05/19]. Available from: <https://www.nice.org.uk/guidance/ng131> [Accessed 03/10/19]
- Jadvar H. 2017. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. *AJR Am J Roentgenol* 209(2): 277-88
- Haberkorn U, Eder M, Kopka K, et al. 2016. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. *Clin Cancer Res* 22(1): 9-15
- Fahey F, Zukotynski K, Capala J, et al. 2014. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. *J Nucl Med* 55(2): 337-48
- Werner RA, Weich A, Kircher M, et al. 2018. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? *Theranostics* 8(22): 6088-100
- Kiesewetter B, Raderer M. 2018. My burning issues in neuroendocrine tumours (NET). *Memo* 11(4): 313-16
- Uri I, Grozinsky-Glasberg S. 2018. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). *Clin Diabetes Endocrinol* 4: 16
- Bomanji J. 2019. Interview with Christine Merkel and Catherine Whicher at The Health Policy Partnership [in person]. 18/09/19
- Buscombe J. 2019. Interview with Catherine Whicher at The Health Policy Partnership [telephone]. 17/10/19
- Versari A. 2019. Interview with Christine Merkel at The Health Policy Partnership [telephone]. 24/10/19
- Parker C, Lewington V, Shore N, et al. 2018. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. *JAMA Oncol* 4(12): 1765-72
- Herrmann K. 2019. Interview with Christine Merkel at The Health Policy Partnership [telephone]. 07/09/19
- Borras JM. 2019. Interview with Christine Merkel at The Health Policy Partnership [telephone]. 07/08/19
- Lahner H. 2019. Interview with Christine Merkel and Catherine Whicher at The Health Policy Partnership [telephone]. 30/09/19
- Rahbar K, Afshar-Oromieh A, Jadvar H, et al. 2018. PSMA Theranostics: Current Status and Future Directions. *Mol Imaging* 17: 1536012118776068
- Du Y, Carrio I, De Vincentis G, et al. 2017. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging* 44(10): 1671-78
- Abbott A, Sakellis CG, Andersen E, et al. 2018. Guidance on (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. *J Nucl Med Technol* 46(3): 237-44
- Jervis N. 2019. Personal communication by email: 04/11/19
- Ambrosini V. 2019. Interview with Christine Merkel and Catherine Whicher at The Health Policy Partnership [telephone]. 03/10/19
- Cwikla J. 2019. Interview with Christine Merkel at The Health Policy Partnership [telephone]. 30/07/19
- World Health Organization. 2018. Cancer. Available from: https://www.who.int/health-topics/cancer#tab=tab_1 [Accessed 06/11/19]
- International Agency for Research on Cancer 2018. 2019. Cancer Tomorrow. Available from: https://gco.iarc.fr/tomorrow/graphic-isotype?type=0&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0#collapse-group-1-7-0 [Accessed 07/06/19]
- Levine R, Krenning EP. 2017. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. *J Nucl Med* 58(Supplement 2): 3S-9S
- McCready VR. 2017. Radioiodine – the success story of Nuclear Medicine. *Eur J Nucl Med Mol Imaging* 44(2): 179-82
- Mitchell AL, Gandhi A, Scott-Coombes D, et al. 2016. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. *J Laryngol Otol* 130(S2): S150-S60
- Filetti S, Durante C, Hartl D, et al. 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*: 10.1093/annonc/mdz400
- Baum RP, Kulkarni HR. 2012. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. *Theranostics* 2(5): 437-47
- Ballinger JR. 2018. Theranostic radiopharmaceuticals: established agents in current use. *Br J Radiol* 91(1091): 20170969-69
- Herrmann K, Larson SM, Weber WA. 2017. Theranostic Concepts: More Than Just a Fashion Trend- Introduction and Overview. *J Nucl Med* 58(Suppl 2): 1s-2s

48. Kulkarni HR, Singh A, Schuchardt C, *et al.* 2016. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. *J Nucl Med* 57(Suppl 3): 97s-104s
49. Bodei L, Kidd M, Baum RP, *et al.* 2014. PRRT: Defining the paradigm shift to achieve standardization and individualization. *J Nucl Med* 55(11): 1753-6
50. International Atomic Energy Agency. Cancer diagnosis. Available from: <https://www.iaea.org/topics/cancer-diagnosis> [Accessed 10/11/19]
51. Society of Nuclear Medicine and Molecular Imaging. 2019. Fact Sheet: What is PET? Available from: <http://www.snm.org/AboutSNMMI/Content.aspx?ItemNumber=5649> [Accessed 25/10/19]
52. Graham MM, Menda Y. 2011. Radiopeptide imaging and therapy in the United States. *J Nucl Med* 52 Suppl 2: 56s-63s
53. Chiti A, van Graafeiland BJ, Savelli G, *et al.* 1999. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. *Ital J Gastroenterol Hepatol* 31 Suppl 2: S190-4
54. Schraml C, Schwenzer NF, Sperling O, *et al.* 2013. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga] DOTATOC multiphase PET/CT and whole-body MRI. *Cancer Imaging* 13(1): 63-72
55. Etchebhere EC, de Oliveira Santos A, Gumz B, *et al.* 2014. ⁶⁸Ga-DOTATATE PET/CT, ^{99m}Tc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. *J Nucl Med* 55(10): 1598-604
56. Pfeifer A, Knigge U, Mortensen J, *et al.* 2012. Clinical PET of neuroendocrine tumors using ⁶⁴Cu-DOTATATE: first-in-humans study. *J Nucl Med* 53(8): 1207-15
57. Pfeifer A, Knigge U, Binderup T, *et al.* 2015. ⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients. *J Nucl Med* 56(6): 847-54
58. Schaffert S, Herrmann K. 2019. A Conversation Between Susanne Schaffert and Ken Herrmann. *J Nucl Med* 60(7): 875-78
59. Malcolm J, Falzone N, Lee BQ, *et al.* 2019. Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. *Cancers (Basel)* 11(2): 268
60. Chaffer CL, Weinberg RA. 2011. A Perspective on Cancer Cell Metastasis. *Science* 331(6024): 1559-64
61. Alfarouk KO, Stock C-M, Taylor S, *et al.* 2015. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. *Cancer Cell Int* 15(1): 71
62. Navalkisoor S, Grossman A. 2019. Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy. *Neuroendocrinology* 108(3): 256-64
63. World Nuclear Association. 2019. Radioisotopes in Medicine. [Updated September 2019]. Available from: <https://www.world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx> [Accessed 06/12/19]
64. World Health Organization. 2008. Radiopharmaceuticals. Available from: <https://www.who.int/medicines/publications/pharmacopoeia/Radgenmono.pdf> [Accessed 05/12/19]
65. Kunikowska J, Króllicki L, Hubalewska-Dydejczyk A, *et al.* 2011. Clinical results of radionuclide therapy of neuroendocrine tumours with ⁹⁰Y-DOTATATE and tandem ⁹⁰Y/¹⁷⁷Lu-DOTATATE: which is a better therapy option? *Eur J Nucl Med Mol Imaging* 38(10): 1788-97
66. Villard L, Romer A, Marinček N, *et al.* 2012. Cohort Study of Somatostatin-Based Radiopeptide Therapy With [⁹⁰Y-DOTA]-TOC Versus [⁹⁰Y-DOTA]-TOC Plus [¹⁷⁷Lu-DOTA]-TOC in Neuroendocrine Cancers. *J Clin Oncol* 30(10): 1100-06
67. Zimmermann RG. 2013. Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals. *Nucl Med Biol* 40(2): 155-66
68. American Society of Clinical Oncology. Cancer progress timeline. Available from: <https://www.asco.org/research-progress/cancer-progress-timeline> [Accessed 08/09/19]
69. PRRTinfo.org. 2019. What is PRRT? Available from: <http://www.prrtinfo.org/prrt> [Accessed 08/09/19]
70. National Cancer Institute at the National Institutes of Health. Milestones in cancer research and discovery. Available from: <https://www.cancer.gov/research/progress/250-years-milestones> [Accessed 08/09/19]
71. US Department of Energy - Molecular Nuclear Medicine Legacy. History of PET and MRI. Available from: <https://www.doemedicalsciences.org/historypetmri.shtml> [Accessed 08/09/19]
72. Whatisbiotechnology.org. Immunotherapy: Timeline of key events. Available from: <https://www.whatisbiotechnology.org/index.php/timeline/science/immunotherapy/80> [Accessed 09/09/19]
73. Krenning EP, Bakker WH, Breeman WA, *et al.* 1989. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. *Lancet* 1(8632): 242-4
74. Krenning EP, Kooij PP, Bakker WH, *et al.* 1994. Radiotherapy with a radiolabeled somatostatin analogue, [¹¹¹In-DTPA-D-Phe¹]-octreotide. A case history. *Ann N Y Acad Sci* 733: 496-506
75. Bander NH, Milowsky MI, Nanus DM, *et al.* 2005. Phase I trial of ¹⁷⁷lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. *J Clin Oncol* 23(21): 4591-601
76. Pecher C. 1942. *Biological investigations with radioactive calcium and strontium; preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer*. Berkeley, Los Angeles, USA: University of California Press
77. Nakajo M, Shapiro B, Copp J, *et al.* 1983. The normal and abnormal distribution of the adrenomedullary imaging agent m-[¹³¹I]iodobenzylguanidine (¹³¹I-MIBG) in man: evaluation by scintigraphy. *J Nucl Med* 24(8): 672-82
78. Francis IR, Glazer GM, Shapiro B, *et al.* 1983. Complementary roles of CT and ¹³¹I-MIBG scintigraphy in diagnosing pheochromocytoma. *AJR Am J Roentgenol* 141(4): 719-25
79. Reddy EK, Robinson RG, Mansfield CM. 1986. Strontium 89 for palliation of bone metastases. *J Natl Med Assoc* 78(1): 27-32
80. Haute Autorite de Sante - Medical EaPHAD. 2014. TRANSPARENCY COMMITTEE: Opinion 1 October 2014 METASTRON. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2015-10/metastron_version_anglaise_ct13569.pdf [Accessed 08/12/19]
81. Medicines and Healthcare products Regulatory Agency. 2016. SUMMARY OF PRODUCT CHARACTERISTICS: METASTRON. Available from: <http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1531718493913.pdf> [Accessed 08/01/20]
82. Kasi PM, Maige CL, Shahjehan F, *et al.* 2018. A Care Process Model to Deliver (¹⁷⁷)Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. *Front Oncol* 8: 663
83. Sartor AO, Fitzpatrick JM. 2012. Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). *BJU Int* 110(3): 328-35
84. Sharma S, Baldi A, Singh R, *et al.* 2018. Regulatory framework of radiopharmaceuticals: current status and future recommendations. *Res J Pharm Biol Chem Sci* 4: 275-90
85. Kim SJ, Pak K, Koo PJ, *et al.* 2015. The efficacy of (¹⁷⁷)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. *Eur J Nucl Med Mol Imaging* 42(13): 1964-70
86. OECD Nuclear Energy Agency. 2019. *The supply of medical radioisotopes: 2019 medical isotope demand and capacity projection for the 2019-2024 period*. Paris, France: OECD
87. European Commission. 2019. Supply of medical radioisotopes. Available from: https://ec.europa.eu/euratom/observatory_radioisotopes.html [Accessed 06/12/19]
88. European Commission. 2009. *Preliminary report on supply of radioisotopes for medical use and current developments in nuclear medicine*. Luxembourg: European Commission
89. OECD Nuclear Energy Agency. 2010. *The supply of medical radioisotopes: An economic study of the molybdenum-99 supply chain*. Paris, France: OECD
90. Academie Nationale de Médecine. 2014. Communiqué, 18 février 2014: TECHNETIUM un risque de pénurie inquiétant pour la santé publique. Available from: <http://www.academie-medecine.fr/wp-content/uploads/2014/02/TechnetiumANM-V5.pdf> [Accessed 06/12/19]
91. OECD Nuclear Energy Agency. 2015. High-level Group on the Security of Supply of Medical Radioisotopes: Fourth mandate (2015-2017). Available from: <http://www.oecd-nea.org/med-radio/security/fourth-mandate.html> [Accessed 06/12/19]

92. Turner JH. 2018. Recent advances in theranostics and challenges for the future. *Br J Radiol* 91(1091): 20170893-93
93. Lievens Y, Audisio R, Banks I, et al. 2019. Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. *Lancet Oncol* 20(2): e112-e23
94. Pang T. 2012. Theranostics, the 21st century bioeconomy and 'one health'. *Expert Rev Mol Diagn* 12(8): 807-09
95. Sowa-Staszczak A, Chrzan R, Pach D, et al. 2012. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors? *Clin Imaging* 36(4): 360-64
96. Pavel ME, Sers C. 2016. WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. *Endocr Relat Cancer* 23(11): T135-t54
97. Segelov E, Chan D, Lawrence B, et al. 2017. Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. *J Glob Oncol* 3(4): 380-88
98. Cives M, Strosberg JR. 2018. Gastroenteropancreatic Neuroendocrine Tumors. *CA Cancer J Clin* 68(6): 471-87
99. European Neuroendocrine Tumor Society. 2018. Incidence and Prevalence of Neuroendocrine Tumors in England. Available from: <https://www.enets.org/incidence-and-prevalence-of-neuroendocrine-tumors-in-england.html> [Accessed 07/10/19]
100. Man D, Wu J, Shen Z, et al. 2018. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. *Cancer Manag Res* 10: 5629-38
101. Leoncini E, Boffetta P, Shafir M, et al. 2017. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. *Endocrine* 58(2): 368-79
102. Basuroy R, Bouvier C, Ramage JK, et al. 2018. Delays and routes to diagnosis of neuroendocrine tumours. *BMC Cancer* 18(1): 1122-22
103. Deppen SA, Liu E, Blume JD, et al. 2016. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. *J Nucl Med* 57(5): 708-14
104. Singh S, Granberg D, Wolin E, et al. 2017. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. *J Glob Oncol* 3(1): 43-53
105. Garcia-Carbonero R, Sorbye H, Baudin E, et al. 2016. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. *Neuroendocrinology* 103(2): 186-94
106. Öberg K, Knigge U, Kwekkeboom D, et al. 2012. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 23(suppl_7): vii124-vii30
107. Öberg K, Hellman P, Ferolla P, et al. 2012. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 23(suppl_7): vii120-vii23
108. Bodei L, Mueller-Brand J, Baum RP, et al. 2013. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours. *Eur J Nucl Med Mol Imaging* 40(5): 800-16
109. Johnbeck CB, Knigge U, Loft A, et al. 2017. Head-to-Head Comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. *J Nucl Med* 58(3): 451-57
110. Romer A, Seiler D, Marincek N, et al. 2014. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. *Eur J Nucl Med Mol Imaging* 41(2): 214-22
111. Bodei L, Cremonesi M, Grana CM, et al. 2011. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. *Eur J Nucl Med Mol Imaging* 38(12): 2125-35
112. Delpassand ES, Samarghandi A, Zamanian S, et al. 2014. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. *Pancreas* 43(4): 518-25
113. Paganelli G, Sansovini M, Ambrosetti A, et al. 2014. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. *Eur J Nucl Med Mol Imaging* 41(10): 1845-51
114. Ezziddin S, Attassi M, Yong-Hing CJ, et al. 2014. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. *J Nucl Med* 55(2): 183-90
115. van Vliet EI, Krenning EP, Teunissen JJ, et al. 2013. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3] octreotate. *J Nucl Med* 54(10): 1689-96
116. Strosberg J, El-Haddad G, Wolin E, et al. 2017. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med* 376(2): 125-35
117. Strosberg J, Wolin E, Chasen B, et al. 2018. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. *J Clin Oncol* 36(25): 2578-84
118. Ferlay J, Colombet M, Soerjomataram I, et al. 2018. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur J Cancer* 103: 356-87
119. Cancer Today - International Agency for Research on Cancer. 2019. Estimated number of cases Europe, both sexes all ages. Available from: <http://bit.ly/2NjXp44> [Accessed 03/10/19]
120. Macedo F, Ladeira K, Pinho F, et al. 2017. Bone Metastases: An Overview. *Oncol Rev* 11(1): 321-21
121. Hague C, Logue JP. 2016. Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases. *Ther Adv Urol* 8(3): 175-80
122. Awang ZH, Essler M, Ahmadzadehfar H. 2018. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches. *Radiat Oncol* 13(1): 98
123. Emmett L, Willowson K, Violet J, et al. 2017. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. *J Med Radiat Sci* 64(1): 52-60
124. Lapa C, Hanscheid H, Kircher M, et al. 2019. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. *J Nucl Med* 60(1): 60-64
125. Lymphoma Action. 2019. What is lymphoma? Available from: <https://lymphoma-action.org.uk/about-lymphoma/what-lymphoma> [Accessed 24/07/19]
126. Salas Fragomeni RA, Amir T, Sheikhabahaei S, et al. 2018. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. *J Nucl Med* 59(6): 871-77
127. Thundimadathil J. 2012. Cancer Treatment Using Peptides: Current Therapies and Future Prospects. *J Amino Acids* 2012: 13
128. BreastCancer.Org. 2018. What is breast cancer? Available from: https://www.breastcancer.org/symptoms/understand_bc/what_is_bc [Accessed 24/07/19]
129. Cancer Research UK. 2018. What is melanoma? Available from: <https://www.cancerresearchuk.org/about-cancer/melanoma/about> [Accessed 24/07/19]
130. Schottelius M, Osl T, Poschenrieder A, et al. 2017. [(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. *Theranostics* 7(9): 2350-62
131. Cancer Research UK. 2018. Myeloma. Available from: <https://www.cancerresearchuk.org/about-cancer/myeloma/about> [Accessed 24/07/19]
132. Cancer Research UK. 2017. About lung cancer. Available from: <https://www.cancerresearchuk.org/about-cancer/lung-cancer/about> [Accessed 24/07/19]
133. Shah M, Da Silva R, Gravekamp C, et al. 2015. Targeted radionuclide therapies for pancreatic cancer. *Cancer Gene Ther* 22(8): 375-79
134. National Health System UK. 2018. Overview: pancreatic cancer [online]. Available from: <https://www.nhs.uk/conditions/pancreatic-cancer/> [Accessed 02/10/19]
135. Herrington W, Lacey B, Sherliker P, et al. 2016. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. *Circ Res* 118(4): 535-46

FOR MORE INFORMATION, PLEASE CONTACT

**Christine Merkel at The Health Policy Partnership:
christine.merkel@hpolicy.com**

© 2020 The Health Policy Partnership Ltd. This report may be used for personal, research or educational use only, and may not be used for commercial purposes. Any adaptation or modification of the content of this report is prohibited, unless permission has been granted by The Health Policy Partnership.